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Does OKT3 Increase the Risk of Recurrent
Hepatitis B in Patients Transplanted for
Hepatitis B?
Levels of HBV-DNA and HbsAg after acute liver
allograft rejection treatment by corticoids and
OKT3. Gonzalez RA, de la Mata M,
de la Torre J, Mino G, Pera C, Pena J, Munoz E.
Clin Transplant 2000:14:208-211. (Reprinted
with permission. r2000 Munksgaard
International Publishers Ltd., Copenhagen,
Denmark.)
Abstract
The aim of this work was to analyze whether the treatment
of acute rejection of orthotopic liver transplants (OLT),
either with corticoids or OKT3, has any effect on levels of
hepatitis B virus (HBV)-DNA and HbsAg in individuals
which were originally affected by cirrhosis or fulminant
hepatic failure as a result of B virus. We have found that
HBV-DNA is present in macrophages, B cells and both
CD41 and CD81 T cells after OLT in all cases studied.
Interestingly, the levels of HBV-DNA and HbsAg in the
serum analyzed were increased extremely rapidly in the
patients treated with OKT3 in an acute rejection episode.
However, the serum levels of HBV-DNA and HbsAg
found were lower when the patients were treated with
steroids, and were not found in non-treated patients. As
the serum levels of HBV-DNA increase, the process of
liver reinfection could be accelerated; therefore, these re-
sults may help to understand how OKT3 and corticoids
immunosuppressive therapy may accelerate the reinfec-
tion of OLT by HBV. In conclusion, our results suggest
that special care must be taken in the use of OKT3 in the
treatment of acute liver rejection episodes in chronic or
fulminant HBV transplanted patients.
Comments
Reactivation of hepatitis B virus (HBV) replication and
exacerbation of liver disease have been reported in pa-
tients with chronic hepatitis B administered immuno-
suppressive or cytotoxic therapy.1-3 Reactivation of
HBV replication may occur not only in patients with
replicative HBV infection (hepatitis B e antigen posi-
tive and detectable serum HBV DNA by non–poly-
merase chain reaction [PCR] assay), but also in patients
with low or nonreplicative infection (hepatitis B e anti-
gen negative and undetectable serum HBV DNA by
non-PCR assay) and those with resolved infection (hep-
atitis B surface antigen [HBsAg] negative, antibody to
HBsAg positive, and antibody to hepatitis B core anti-
gen positive). This is related to the persistence of HBV,
albeit at low levels, in the liver and circulating blood
and the presence of HBV DNA in extrahepatic reser-
voirs, especially peripheral-blood mononuclear cells
(PBMCs).4,5
Among the immunosuppressive agents used after
orthotopic liver transplantation (OLT), corticosteroids
may have the most potent effect on HBV replication. In
addition to indirect effects through immunosuppres-
sion, corticosteroids may directly augment HBV repli-
cation through a glucocorticoid-responsive element in
the HBV genome.6 Other antirejection drugs, such as
cyclosporine and tacrolimus, were reported to have no
direct stimulatory effect on HBV replication.7,8
The effects of other antirejection therapies, such as
OKT3 (Orthoclone OKT3; Ortho Biotech Inc, Rari-
tan, NJ, and muromonab CD3), on HBV replication
have not been studied. OKT3, a monoclonal antibody
against T cells, induces a rapid lymphocytopenia gen-
erally attributed to lymphocyte opsonization and
phagocytosis.9,10 It also modulates the expression of the
T-cell receptor complex so that T cells become blinded
to the antigens presented by the allograft.9,10 Further-
more, T-cell homocytolysis,11 as well as apoptosis,12
have been proposed as possible mechanisms of action of
OKT3. The use of OKT3 in patients who underwent
OLT for hepatitis C has been associated with early and
severe recurrence of hepatitis C.13,14
In the study by Gonzalez et al,15 11 patients who
underwent OLT for hepatitis B and developed acute
rejection were studied. All patients were administered
low-dose hepatitis B immune globulin (HBIG) intra-
muscularly (IM) as prophylaxis against HBV reinfec-
tion. No patient was administered antiviral therapy.
Rejection episodes were treated with 3 doses of meth-
ylprednisolone and/or an increased dosage of oral pred-
nisone. Steroid-resistant rejection episodes were treated
with OKT3 for 10 to 14 days. Three patients were
administered corticosteroids and OKT3, 6 patients
were administered corticosteroids only, and 2 patients
were not treated. All 3 patients treated with OKT3
developed high serum HBV DNA levels, and 2 of these
patients died of recurrent hepatitis B during the second
and third years post-OLT. Serum HBV DNA was
present at low levels in 3 of the 6 patients treated with
corticosteroids alone, but not in the 2 patients who were
not treated. The investigators suggested that OKT3
may lead to a rapid increase in serum HBV DNA levels
in patients who undergo OLT for hepatitis B and cau-
tioned that special care be exercised when OKT3 is
administered to these patients. They speculated that the
devastating effects of OKT3 may be related to the re-
lease of viral particles secondary to lysis of T cells, re-
lease of cytokines that may facilitate entry of HBV into
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hepatocytes and other cells, or activation of HBV rep-
lication within PBMCs by mitogens. These hypotheses
are interesting and need to be tested. Although the
investigators showed increasing serum HBV DNA lev-
els in the 3 patients administered OKT3, the findings
were based on a small number of patients tested at very
few time points, and details about these 3 patients in
relation to the other patients, such as total dose and
duration of corticosteroid therapy and viral replication
status before OLT and just before the rejection episode,
were not provided. Thus, more data are needed to de-
termine whether the use of OKT3 is associated with a
more rapid increase in serum HBV DNA levels in pa-
tients who undergo OLT for hepatitis B.
Deciphering the mechanisms by which OKT3 in-
creases serum HBV DNA levels is more difficult. Using
PCR assay, the investigators found HBV DNA present
in CD41 and CD81 T cells, B cells, and macrophages
even before the rejection episode. It is possible that
OKT3-mediated lysis of T cells results in the release of
HBV DNA into the circulation. Whether lymphokines
induced by OKT3 facilitated the entry of HBV into
hepatocytes or promoted HBV replication is less cer-
tain. Currently, very few data exist on the mechanisms
of entry of HBV into hepatocytes and other cells. Some
of the lymphokines induced by OKT3, such as interfer-
on-g and tumor necrosis factor, have been shown to
downregulate HBV expression.16,17 Some studies sug-
gested that HBV can replicate in PBMCs, but these
findings are controversial.18,19 It is more likely that the
effects of OKT3 on HBV replication are mediated
through reduced immune-mediated virus clearance
through lymphocyte depletion and antigenic modula-
tion of the T-cell receptor complex.
The important clinical question is what to do when
patients who undergo OLT for hepatitis B develop an
episode of rejection. It is obvious that these patients
should continue to be administered prophylaxis for
HBV reinfection. Currently, the most effective thera-
pies include long-term, high-dose, intravenous HBIG
or combination therapy with HBIG and lamivu-
dine.20,21 Because of the expense associated with high-
dose intravenous HBIG, many centers are evaluating
the efficacy of lower doses, shorter duration, or IM
administration of HBIG in combination with lamivu-
dine. The short-term efficacies of these regimens are
impressive, but longer follow-up of a larger number of
patients is needed to determine the most cost-effective
prophylactic regimen for patients who undergo OLT
for hepatitis B. The efficacy of IM HBIG alone has not
been well documented and may account for the high
reinfection rate reported by Gonzalez et al.15 Even in
patients administered adequate prophylaxis, the occur-
rence of rejection episodes necessitating more aggressive
immunosuppressive therapy may increase the risks for
HBV reinfection. In vitro studies using the human
hepatoblastoma cell line showed that the addition of
antiviral therapy can inhibit the increase in HBV repli-
cation induced by prednisolone and azathioprine.7 It
seems reasonable to consider the addition of lamivudine
in patients administered HBIG monotherapy and
closely monitor the antibody to HBsAg titer to deter-
mine whether greater or additional doses of HBIG
should be administered to patients administered IM
HBIG with or without lamivudine when patients who
underwent transplantation for hepatitis B develop ste-
roid-resistant rejection episodes necessitating OKT3
therapy.
Although significant progress has been made in the
prevention of recurrent hepatitis B after OLT, much
remains to be learned. Adequate prophylaxis should be
administered to all patients, and close monitoring is
required, especially in patients with replicative infection
pre-OLT or who require more intense immunosup-
pression post-OLT. The effects of more selective anti-
rejection drugs, such as anti–interleukin-2 receptor an-
tibody, on HBV replication should be evaluated.
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Detecting Alcoholic Relapse Posttransplant
Carbohydrate-deficient transferrin is not a useful
marker for the detection of chronic alcohol
abuse. Schmitt VM, Stieber P, Jungst D, Blizer M,
Wachtler M, Heberger S. Eur J Clin Invest 1998;
28:615-621. (Reprinted with permission.)
Abstract
Background: The role of carbohydrate-deficient trans-
ferrin (CDT) as a reliable marker for the detection of
chronic alcohol abuse has been discussed controversially.
Methods: Therefore, we investigated CDT in the sera from
405 subjects with different alcohol intake. Besides healthy
control subjects (n 5 42), inpatients and outpatients in a
department of gastroenterology (n 5 325) and patients
admitted to a department of otorhinolarynology (n 5 38)
were studied. A total of 213 patients suffered from various
forms of liver diseases, and 89 patients had liver transplan-
tation. CDT values were determined by a double-anti-
body radioimmunoassay.
Results: In the 241 alcohol-abstinent subjects, CDT levels
ranged from 3 to 90 units L-1 (median 5 12); the 92 mod-
erate drinkers (20-60 g of alcohol per day) showed values
from 3 to 40 units L-1 (median 5 12), and the 72 subjects
with chronic alcohol abuse (> 60 g per day) revealed CDT
levels from 3 to 100 units L-1 (median 5 16). The diag-
nostic specificity for alcohol abuse was 86.8% for men
(sensitivity 36.9%) and 95% for women (sensitivity 0%).
Conclusion: Our data indicate that measurement of CDT
does not reach clinical use in the detection of chronic
alcohol abuse in an unselected population because of its
insufficient specificity and sensitivity.
Comments
Alcohol-related liver disease accounts for up to 50% of
the patients who die of end-stage liver disease.1 Patients
with alcoholic cirrhosis have posttransplantation sur-
vival rates similar to those for patients who undergo
transplantation for non–alcohol-related liver disease.2-4
However, relapse has been a significant concern in this
population. Most studies report relapse rates after trans-
plantation of 0% to 30%.5 These studies used various
definitions of relapse. Campbell et al6 reported a small
minority of patients who returned to problematic
drinking, leading to rehospitalization and, in some
cases, death.
The search for a way to detect alcohol use after
transplantation has included developing biochemical
markers that reliably detect relapse. Abnormalities in
transferrin levels, later named carbohydrate-deficient
transferrin (CDT), were found in the cerebrospinal
fluid of patients with alcohol cerebellar degeneration in
1976,7 and later, in the serum of alcohol abusers.8 Since
then, CDT has been studied as a marker of excessive
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